Topical and Systemic Retinoids in the Geriatric Population
Özet
Retinoids are defined as molecules that activate cellular proliferation and differentiation by binding to retinoic acid receptors. Since they are not produced in the body, they need to be obtained externally through food. Retinoids have natural and synthetic forms. Topical and systemic retinoids are used in the treatment of many diseases in geriatric dermatology. In the literature, there are limited studies and data regarding the use, efficacy, and side effects of retinoids in the geriatric population over the age of 65. It has been reported that topical retinoic acids may cause more irritation in patients aged 65 and above. Due to lower tolerance in the geriatric population, it is suggested that systemic retinoids should be started and used at lower doses compared to younger individuals. Although there is no specific dose recommendation for systemic retinoids in the geriatric population, data on their use, efficacy, and side effects are limited. Whether the treatment response differs from that of younger patients is not fully known. When adjusting the dose for patients, the reduced hepatic, renal, and cardiac functions in the geriatric population should be considered, and the lowest possible doses should be used.
Referanslar
Taşlı L. Retinoids. In: Tüzün Y, Serdaroğlu S, Erdem C, Özpoyraz M, Önder M, Öztürkcan S, Dermatology Treatments. Istanbul: Nobel Medical Bookstore. 2020:962-968.
Melika Motamedi et al. Clinician’s Guide to Topical Retinoids. Journal of Cutaneous Medicine and Surgery. 2022 Jan; 26(1): 71–78.
Samar Khalil, T. B. Retinoids: A Journey from the Molecular Structures and Mechanisms of Action to Clinical Uses in Dermatology and Adverse Effects. Journal of Dermatological Treatment, 2017 Dec; 28(8):684-696.
Helen B. Everts, Eleonore-Nausica Akuailou. Retinoids in Cutaneous Squamous Cell Carcinoma. Nutrients. 2021 Jan; 13(1): 153.
Saurat J-H, Sorg O. Retinoids. In: Bolognia JL, Schaffer JV, Cerroni L, eds. Dermatology. 4th Ed. Elsevier Limited. 2018. p. 2200–2214.
Santhosh P, Kidangazhiathmana A. Trifarotene - The latest retinoid. Indian J Dermatol Venereol Leprol. 2021 Sep-Oct;87(5):742-745. doi: 10.25259/IJDVL_741_20. PMID: 34245524.
Karaali M, Gürel MS. Topical Treatment in Dermatology. In: Gürel MS, Aksu AE, Durdu M, Erdemir VA, Karadağ AS. Basic Dermatology. Istanbul Medical Bookstore. 2020. p. 1125-1126.
Şanlı, H. and Yıldızhan, I. K. Topical Treatments. TURKDERM - Turkish Archives of Dermatology and Venereology. 2020; 54(1): 23-29.
Wolverton, S. E. Comprehensive Dermatologic Drug Therapy, Fourth Edition, Comprehensive Dermatologic Drug Therapy, Fourth Edition. 2020.
Chang, A. L. S. Advances in Geriatric Dermatology, Advances in Geriatric Dermatology. January 2015.
Renova cream (tretinoin) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; March 2017.
Renova cream (tretinoin) [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; September 2019.
Adışen E. Tazarotene. In: Alpsoy E, Ergun T, Şendur N. Comprehensive Psoriasis. Istanbul: Galenos Publishing. 2020. p. 204-210.
Bianchi, L. et al. Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases, The British Journal of Dermatology. 2004; 151(1): 148–156.
Tazarotene cream (tazarotene) [prescribing information]. Raleigh, NC: Mayne Pharma; 2022.
Tazarotene Cream 0.1% (tazarotene) [prescribing information]. Hawthorne, NY: Taro Pharmaceuticals U.S.A.; 2017.
Targretin gel (bexarotene) [prescribing information]. Buffalo, NY: Pharmaceuticals Limited Niagara; 2000.
Ana Arechalde, J.H. Saurat. Retinoids: unapproved uses or indications. Clinics in Dermatology. 2000 Jan-Feb;18(1):63-76.
Yamauchi P. S. Biologic and Systemic Agents in Dermatology. Switzerland: Springer. 2018:281-282.
Piaserico S, et al. Efficacy and safety of systemic treatments for psoriasis in elderly patients. Acta Derm Venereol. 2014 May;94(3):293-7.
Dogra S, Jain A, Kanwar A.J. Efficacy and safety of acitretin in three fixed doses of 25, 35, and 50 mg in adult patients with severe plaque-type psoriasis: a randomized, double-blind, parallel-group, dose-ranging study. J Eur Acad Dermatol Venereol. 2013 Mar;27(3):e305-11.
Wakelin, S. H., Maibach, H. I., and Archer, C. B. Handbook of Systemic Drug Treatment in Dermatology: Second Edition. 2015. doi: 10.1201/b18491.
Karadağ AS. Acitretin. In: Alpsoy E, Ergun T, Şendur N. Comprehensive Psoriasis. Istanbul: Galenos Publishing. 2020. p. 257-276.
Kakşi S. Geriatric Dermatology. In: Gürel MS, Aksu AE, Durdu M, Erdemir VA, Karadağ AS. Basic Dermatology. Istanbul Medical Bookstore. 2020. p. 970-971.
Pearce D et al. Low-dose acitretin is associated with fewer adverse events than high-dose acitretin in the treatment of psoriasis. Arch Dermatol. 2006 Aug;142(8):1000-4.
Katz HI, W. J. Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol. 1999 Sep;41(3 Pt 2): S7-S12.
Nast A, G. P. European S3-Guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2015 Dec;29(12):2277-94.
Roenigk H, C. J. Effects of acitretin on the liver. J Am Acad Dermatol. 1999 Oct;41(4):584-8.
Kılıç MP. Systemic Treatments and Monitoring. In: Gürel MS, Aksu AE, Durdu M, Erdemir VA, Karadağ AS. Basic Dermatology. Istanbul Medical Bookstore. 2020. p. 1096-1099.
Targretin (bexarotene capsule) [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; 2020.
Blair, H. A., and Scott, L. J. Alitretinoin: A Review in Severe Chronic Hand Eczema. Drugs. 2016; 76:1271–1279.
Nast A, B. D. European evidence-based (S3) guideline for the treatment of acne – update 2016 – short version. J Eur Acad Dermatol Venereol, 2016 Aug;30(8):1261-8.
FDA. FDA approved drug products: Accutane oral capsule; August 24, 2023. Retrieved from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018662.
Paichitrojjana, A. P. Oral Isotretinoin and Its Uses in Dermatology: A Review. Drug Des Devel Ther. 2023 Aug 25;17:2573-2591.
Dessinioti C, Z. C. Comparison of guidelines and consensus articles on the management of patients with acne with oral isotretinoin. J Eur Acad Dermatol Venereol. 2020 Oct;34(10):2229-2240.
Goulden V, C. S. Treatment of acne with intermittent isotretinoin. Br J Dermatol. 1997 Jul;137(1):106-8.
Layton, A. The use of isotretinoin in acne. Dermatoendocrinol. 2009 May;1(3):162-9.
Azoulay L, O. D. Isotretinoin therapy and the incidence of acne relapse: a nested case-control study. Br J Dermatol. 2007 Dec;157(6):1240-8.
Layton AM, K. H. Isotretinoin for acne vulgaris-10 years later; a safe and successful treatment. Br J Dermatol. 1993 Sep;129(3):292-6.
Stainforth JM, L. A. Isotretinoin for the treatment of acne vulgaris: which factors may predict the need for more than one course? Br J Dermatol. 1993 Sep;129(3):297-301.
D C Seukeran, W. J. Acne vulgaris in the elderly: the response to low-dose isotretinoin. Br J Dermatol. 1998 Jul;139(1):99-101.
Sarah H. Wakelin, H. I. Handbook of Systemic Drug Treatment in Dermatology. Boca Raton: CRC Press. 2023.
